TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24180699
Drug: Tramadol 5
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 5 mg/kg
Study: 24180699
Drug: Tramadol 10
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 10 mg/kg
Study: 19933175
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 50 mg kg(‐1) for 15 min and then 15 mg kg(‐1) h(‐1) by continuous i.v. infusion until the end of surgery
Study: 29121334
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg dronabinol
Study: 7393998
Drug: High-dose Fluphenazine-Decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose Fluphenazine-Decanoate (average dose 225 mg in 14 days)
Study: 7393998
Drug: Standard-dose Fluphenazine-Decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose Fluphenazine-Decanoate (25 mg in 14 days)
Study: 7393998
Drug: High-dose Fluphenazine-Decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose Fluphenazine-Decanoate
Study: 7393998
Drug: Standard-dose Fluphenazine-Decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose Fluphenazine-Decanoate
Study: 31127468
Drug: Integrated consent
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated consent model (ICM) with oral consent
Study: 31127468
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care interventions (including surgical, adjuvant chemotherapy, supportive care, radiology, vascular devices, palliative care, molecular diagnostics)
Study: 26033220
Drug: neoadjuvant axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neoadjuvant axitinib therapy
Study: 17472820
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 to 10 mg + Valsartan 160 mg
Study: 17472820
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 to 20 mg + HCTZ 12.5 mg
Study: 15262126
Drug: CMC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMC regimen (carboplatin 1500 mg/m², mitoxantrone 75 mg/m², cyclophosphamide 120 mg/kg)
Study: 15262126
Drug: CTC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC regimen (cisplatin 165 mg/m², thiotepa 600 mg/m², cyclophosphamide 5625 mg/m²)
Study: 10682563
Drug: Metoprolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol plus routine therapy
Study: 8565696
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AG and hydroxyprogesterone caproate
Study: 2474097
Drug: Captopril or
Normalized name: captopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril or Enalapril (ACE inhibitors) for 2-6 months
Study: 2474097
Drug: Captopril or
Normalized name: captopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril or Enalapril combined with Mepitiostane (antiestrogenic steroid)
Study: 105098
Drug: Levamisole therapy
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole therapy
Study: 28555508
Drug: Conventional 120‐kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 120‐kVp scan with a CM volume of 70 ml and an injection rate of 5 ml s‐1 (Group A)
Study: 28555508
Drug: ssDECT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ssDECT scan with CM volume of 0.6 ml/kg and 40% ASIR (Group B)
Study: 28555508
Drug: ssDECT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ssDECT scan with CM volume of 0.4 ml/kg and 50% ASIR (Group C)
Study: 16584285
Drug: Tagamet 400mg
Normalized name: Tagamet 400mg Tablet
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tagamet 400mg tablet
Study: 16584285
Drug: 7.5% methacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% methacrylate copolymer cimetidine tablet
Study: 16584285
Drug: 15% methacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% methacrylate copolymer cimetidine tablet
Study: 16584285
Drug: 26% methacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26% methacrylate copolymer cimetidine tablet
Study: 16584285
Drug: Tagamet (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagamet (300 mg/2 mL) intravenous injection
Study: 12706917
Drug: Eptifibatide 180
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide 180 microg/kg bolus, 2 microg/kg/min infusion, and 180 microg/kg bolus 10 min later (180/2/180) plus half-dose TNK (0.27 mg/kg)
Study: 12706917
Drug: Standard-dose TNK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose TNK monotherapy (0.53 mg/kg)
Study: 11097963
Drug: Imipramine (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (180 mg/day)
Study: 11097963
Drug: Buspirone (38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (38 mg/day)
Study: 6385868
Drug: Cimetidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (20 mg/kg/day)
Study: 6385868
Drug: Antacids (Maalox,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (Maalox, 700 mmol (mEq)/1 X 73 m2/day)
Study: 27893563
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - Usual care and maintenance of daily activities
Study: 25963053
Drug: Positive post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Positive post-treatment biopsy
Study: 21622815
Drug: Centrally placed
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally placed polyethylene screw and sheath implant (INTRAFIX)
Study: 18452437
Drug: Curcuminoids hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids hydrogel patch with squid chitosan (1:1 ratio of curcuminoids microemulsion to polymer solution)
Study: 18452437
Drug: Curcuminoids hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids hydrogel patch with squid chitosan
Study: 18452437
Drug: Curcuminoids hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids hydrogel patch
Study: 16490726
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propacetamol 2 g and ketorolac 30 mg
Study: 9188930
Drug: 0.05% mequitazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% mequitazine eye-drops, four times daily for 5 days
Study: 8166477
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by aggressive randomized chemotherapy and PCI
Study: 8166477
Drug: Preoperative (neoadjuvant)
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative (neoadjuvant) chemotherapy followed by surgery
Study: 29064536
Drug: No-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-therapy
Study: 22917554
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil (6 μg/breath, 3 to 9 breaths, 4 times/day)
Study: 17923329
Drug: no-treatment, standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-treatment, standard care only control
Study: 15906109
Drug: Cross‐linked hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross‐linked hylan G‐F 20 (group II)
Study: 9041079
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon alpha 2b (IFN‐alpha) 5 x 10(6) IU/ml, four times daily for 4 weeks
Study: 9041079
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon alpha 2b (IFN‐alpha) for patients with correction > 5.00 D
Study: 9041079
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon alpha 2b (IFN‐alpha)
Study: 1552999
Drug: Intravenous 1-alpha-hydroxyvitamin
Normalized name: 1α-hydroxyvitamin D2
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) after each dialysis at increasing doses up to 4 micrograms, with Mg(OH)2 as sole phosphate binder.
Study: 1552999
Drug: Intravenous 1-alpha-hydroxyvitamin
Normalized name: 1α-hydroxyvitamin D2
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) with Mg(OH)2 as sole phosphate binder.
Study: 3991397
Drug: Diumide K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diumide K (frusemide 40 mg, potassium 8 mmol)
Study: 3991397
Drug: Burinex K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burinex K (bumetanide 0.5 mg, potassium 7.7 mmol)
Study: 22268900
Drug: Semantic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantic therapy (two 15-min sessions per week for 8 weeks) targeting words from semantic categories (animals, food, clothes)
Study: 22268900
Drug: Waiting control
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting control group (no therapy in Phase 1)
Study: 22268900
Drug: Combined effect
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined effect of therapy over the two groups
Study: 22268900
Drug: Pre-therapy TAWF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-therapy TAWF scores
Study: 22268900
Drug: Post-therapy TAWF
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-therapy TAWF scores
Study: 7562730
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent neutral NaF solution rinsed once a week
Study: 7562730
Drug: 2.2 mg
Normalized name: menthol 2.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 mg NaF tablet chewed, rinsed, and swallowed daily
Study: 7562730
Drug: Both procedures
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both procedures (mouthrinse and tablet)
Study: 31341122
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment (DT) perceived as a cause of OMLs
Study: 31341122
Drug: Chief complaint
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chief complaint site (CC)
Study: 20374670
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation therapy, provided weekly for 4 months followed by monthly sessions for 4 months.
Study: 17493183
Drug: Cefepime 1
Normalized name: cefepime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 1 g intramuscularly every 24 hours
Study: 17493183
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g intramuscularly every 24 hours
Study: 2248837
Drug: Diclofenac 1
Normalized name: diclofenac 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1 mg kg‐1 i.m.
Study: 2248837
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic (placebo)
Study: 24193288
Drug: Absorbable fibrin
Normalized name: TachoSil Absorbable Fibrin Sealant Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable fibrin sealant patch (AFSP)
Study: 24193288
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment (ST)
Study: 24193288
Drug: Absorbable fibrin
Normalized name: TachoSil Absorbable Fibrin Sealant Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable fibrin sealant patch (AFSP) and Standard surgical treatment (ST)
Study: 19214861
Drug: 1064 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1064 nm Nd:YAG laser treatment (fluence 30 J/cm, 18 mm spot size, dynamic cooling device pulse duration of 30 ms)
Study: 11913309
Drug: AHDC chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHDC chewing gum (5% sodium bicarbonate), 2 tablets for 20 minutes, 2 times daily
Study: 11913309
Drug: Mint tablet
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mint tablet (sugarless), 2 tablets for 20 minutes, 2 times daily
Study: 7701191
Drug: Modafinil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (300 mg daily)
Study: 3588258
Drug: Adjuvant oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oxygen therapy for 48 hours
Study: 29283132
Drug: Oral fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fenofibrate 160 mg/day
Study: 29283132
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol (Control Group B)
Study: 28814275
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose monotherapy (S-1 30 mg/m2 twice daily days 1-14 every 3 weeks, followed by second line irinotecan 250-350 mg/m2 iv day 1 every 3 weeks or 180-250 mg/m2 iv day 1 every 2 weeks)
Study: 28814275
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose combination therapy (S-1 20 mg/m2 days 1-14 + oxaliplatin 100 mg/m2 iv day 1 every 3 weeks, followed by second line S-1 20 mg/m2 days 1-14 + irinotecan 180 mg/m2 day 1 every 3 weeks)
Study: 26316345
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg BID
Study: 23292524
Drug: Atropine treatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine treatment for myopia
Study: 8867520
Drug: terguride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: terguride (1 mg b.i.d.)
Study: 8867520
Drug: levodopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa (250 mg p.o.)
Study: 1638712
Drug: Enalapril (2.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5-20 mg/day)
Study: 15859528
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) treatment of the lower extremity
Study: 12602111
Drug: Pulsed magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed magnetic field therapy
Study: 7582337
Drug: Wet-to-dry saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet-to-dry saline gauze dressings changed twice a day
Study: 1660009
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10,000 anti Xa units of LMWH
Study: 1660009
Drug: Aortic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aortic administration before clamping of 10,000 anti Xa units of LMWH
Study: 1660009
Drug: Intra-aortic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic administration of 10,000 anti Xa units of LMWH
Study: 1660009
Drug: Aortic injection
Normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic injection after clamping of 10,000 anti Xa units of LMWH
Study: 26778165
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral β blockers (administered ≤24 hours after hospital admission)
Study: 26778165
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral β blockers (administered >24 hours after hospital admission)
Study: 25484042
Drug: ch‐mAb7F9, doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: ch‐mAb7F9, doses of 0.2 to 20 mg/kg
Study: 18839190
Drug: Ultrasound-guided steroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided steroid injections
Study: 18839190
Drug: Palpation-guided steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided steroid injections
Study: 18839190
Drug: Scintigraphy-guided steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scintigraphy-guided steroid injections
Study: 18839190
Drug: Comparison among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison among ultrasound-guided, palpation-guided, and scintigraphy-guided injections
Study: 8276367
Drug: Glypressin (2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glypressin (2-mg injection)
Study: 2735328
Drug: sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 2 g at night
Study: 2735328
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg
Study: 1172718
Drug: Warfarin sodium
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin sodium added to chemotherapy
Study: 31220851
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of TLD (29 W and 32 W)
Study: 26055693
Drug: New reduced-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: New reduced-dose Td vaccine
Study: 26055693
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available Td vaccine
Study: 21114896
Drug: Cognitive Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Control (CC) task
Study: 18289563
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg intravenous papaverine hydrochloride
Study: 18289563
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg intramuscular sodium diclofenac
Study: 16048734
Drug: Zolpidem (ZOL)
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem (ZOL) 10 mg orally
Study: 16048734
Drug: Brotizolam (BTM)
Normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam (BTM) 0.25 mg orally
Study: 12480612
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation, 300 mg, twice daily for 28 days
Study: 11190906
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg of aspirin every third day
Study: 11190906
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg of aspirin every day
Study: 11190906
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg of aspirin every third day
Study: 11190906
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of aspirin every third day
Study: 8422561
Drug: Chlormezanone 400
Normalized name: chlormezanone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormezanone 400 mg nocte
Study: 25564105
Drug: Short-term medication-assisted
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term medication-assisted treatment (ST-MAT) with buprenorphine/naloxone (BUP/NX) for 1 year, including 2 opportunities for a 15-day detoxification and up to 21 sessions of behavioral drug and risk counseling
Study: 25564105
Drug: Long-term medication-assisted
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medication-assisted treatment (LT-MAT) with buprenorphine/naloxone (BUP/NX) for 48 weeks, including thrice-weekly dosing and up to 21 counseling sessions
Study: 21112449
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment program focused on weight loss
Study: 21112449
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment program focused on both weight loss and depression
Study: 9310604
Drug: G‐CSF (filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (filgrastim) therapy
Study: 3543342
Drug: Butoconazole vaginal
Normalized name: butoconazole Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butoconazole vaginal cream
Study: 27413037
Drug: Heart failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart failure medication regimen (intense treatment)
Study: 27413037
Drug: Higher blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher blood pressure and treatment with a β‐blocker or randomized to valsartan
Study: 11515716
Drug: C-Med-100, 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-Med-100, 350 mg x 2 daily for two months
Study: 29614521
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg twice daily or intravenous argatroban
Study: 29614521
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 40 mg once daily
Study: 24427665
Drug: Clonidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (5 µg/Kg)
Study: 10634816
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg/d for 2 weeks)
Study: 1556522
Drug: Evening insulin
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening insulin therapy (Monotard HM or Ultratard HM), initial dose 10-16 U, mean dose 23 U d‐1 at 12 months